- Home
- RILY vs MIST Comparison
RILY vs MIST Comparison
Compare RILY & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RILY | MIST |
|---|---|---|
| Founded | 1973 | 2003 |
| Country | United States | Canada |
| Employees | 2056 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.6M | 176.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | RILY | MIST |
|---|---|---|
| Price | $7.80 | $1.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 578.4K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.67 | $0.63 |
| 52 Week High | $10.97 | $3.06 |
Technical Indicators
Market Signals| Indicator | RILY | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 47.59 |
| Support Level | $4.78 | $1.62 |
| Resistance Level | $10.97 | $1.79 |
| Average True Range (ATR) | 0.50 | 0.07 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 93.01 | 78.00 |
Price Performance
Historical ComparisonAbout RILY B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).